目的 探讨裸花紫珠颗粒联合莫西沙星片治疗慢性盆腔炎的临床效果。方法 收集2020年4月—2023年4月东部战区总医院收治的75例慢性盆腔炎患者的临床资料，根据用药方案不同将75例慢性盆腔炎患者分为对照组（37例）和治疗组（38例）。对照组口服莫西沙星片，0.4 g/次，1次/d。治疗组在对照组基础上开水冲服裸花紫珠颗粒，3 g/次，3次/d。两组持续治疗2周。比较两组临床疗效、临床症状缓解时间、生活质量、血清炎症因子和复发情况。结果 对照组的总有效率为70.27%，治疗组的总有效率为94.74%，组间比较差异有显著性（P＜0.05）。治疗组的白带异常、下腹部疼痛、发热缓解时间明显短于对照组（P＜0.05）。治疗后，两组血清白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）、单核细胞趋化蛋白1（MCP-1）水平均降低（P＜0.05），治疗组的血清IL-1β、TNF-α、MCP-1水平明显低于对照组（P＜0.05）。随访后，两组WHOQOL-BREF评分均显著升高（P＜0.05），治疗组的WHOQOL-BREF评分明显高于对照组（P＜0.05）。治疗组复发率低于对照组，差异有统计学意义（P＜0.05）。结论 慢性盆腔炎患者采用裸花紫珠颗粒联合莫西沙星片治疗可提高临床疗效，缩短临床症状改善时间，提高患者生活质量，降低患者炎症因子水平和复发率。

Objective To explore the clinical effect of Luohuazizhu Granules combined with Moxifloxacin Tablets in treatment of chronic pelvic inflammatory disease. Methods Clinical data of 75 patients with chronic pelvic inflammatory disease admitted to Eastern Theater General Hospital from April 2020 to April 2023 were collected. Patients with chronic pelvic inflammatory disease were divided into control group (37 cases) and treatment group (38 cases) according to different medication regimens. The control group took Moxifloxacin Tablets orally, 0.4 g/time, once daily. The treatment group were po administered with Luohuazizhu Granules in boiling water on the basis of the control group, 3 g/time, 3 times daily. Two groups received continuous treatment for 2 weeks. The clinical efficacy, symptom relief time, quality of life, serum inflammatory factors, and recurrence were compared between two groups. ResultsThe total effective rate of the control group was 70.27%, while the total effective rate of the treatment group was 94.74%, and the difference between two groups was significant (P < 0.05). The relief time of abnormal vaginal discharge, lower abdominal pain, and fever in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the serum levels of IL-1β, TNF-α, and MCP-1 in two groups were decreased (P < 0.05), and the serum levels of IL-1β, TNF-α, and MCP-1 in the treatment group were significantly lower than those in the control group (P < 0.05). After follow-up, WHOQOL-BREF scores in two groups were significantly increased (P < 0.05), and WHOQOL-BREF scores in the treatment group were significantly higher than those in the control group (P < 0.05). The recurrence rate of the treatment group was lower than that of the control group, and the difference was statistically significant (P < 0.05). Conclusion The combination of Luohuazizhu Granules and Moxifloxacin Tablets in treatment of chronic pelvic inflammatory disease can improve clinical efficacy, shorten the time for clinical symptom improvement, improve patients' quality of life, reduce inflammation factor levels and recurrence rates

R984

东部战区总医院临床诊疗新技术项目（22LCZLXJS30）